Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts by DuBose, Amanda J. et al.
Everolimus rescues multiple cellular
defects in laminopathy-patient fibroblasts
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation DuBose, Amanda J., Stephen T. Lichtenstein, Noreen M. Petrash,
Michael R. Erdos, Leslie B. Gordon, and Francis S. Collins. 2018.
“Everolimus rescues multiple cellular defects in laminopathy-
patient fibroblasts.” Proceedings of the National Academy of
Sciences of the United States of America 115 (16): 4206-4211.
doi:10.1073/pnas.1802811115. http://dx.doi.org/10.1073/
pnas.1802811115.
Published Version doi:10.1073/pnas.1802811115
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37067612
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Everolimus rescues multiple cellular defects in
laminopathy-patient fibroblasts
Amanda J. DuBosea, Stephen T. Lichtensteina, Noreen M. Petrasha, Michael R. Erdosa, Leslie B. Gordonb,c,
and Francis S. Collinsa,1
aGenome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; bDepartment of Pediatrics,
Hasbro Children’s Hospital and Warren Alpert Medical School of Brown University, Providence, RI 02903; and cDepartment of Anesthesia, Boston Children’s
Hospital and Harvard Medical School, Boston, MA 02115
Contributed by Francis S. Collins, February 28, 2018 (sent for review June 1, 2016; reviewed by Thomas W. Glover and Giovanna Lattanzi)
LMNA encodes the A-type lamins that are part of the nuclear scaf-
fold. Mutations in LMNA can cause a variety of disorders called
laminopathies, including Hutchinson-Gilford progeria syndrome
(HGPS), atypical Werner syndrome, and Emery-Dreifuss muscular
dystrophy. Previous work has shown that treatment of HGPS cells
with the mTOR inhibitor rapamycin or with the rapamycin analog
everolimus corrects several of the phenotypes seen at the cellular
level—at least in part by increasing autophagy and reducing the
amount of progerin, the toxic form of lamin A that is overpro-
duced in HGPS patients. Since other laminopathies also result in
production of abnormal and potentially toxic lamin proteins, we
hypothesized that everolimus would also be beneficial in those
disorders. To test this, we applied everolimus to fibroblast cell
lines from six laminopathy patients, each with a different muta-
tion in LMNA. Everolimus treatment increased proliferative ability
and delayed senescence in all cell lines. In several cell lines, we
observed that with treatment, there is a significant improvement
in nuclear blebbing, which is a cellular hallmark of HGPS and other
lamin disorders. These preclinical results suggest that everolimus
might have clinical benefit for multiple laminopathy syndromes.
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Laminopathies are a diverse group of disorders caused by adefect in the proteins that make up the nuclear lamina, which
is composed of intermediate filament proteins called lamins. In
humans, the major lamins are lamin A, lamin B1, lamin B2, and
lamin C. All of the A-type lamins, including lamins A and C, are
alternatively spliced from the LMNA gene (1). There are many
laminopathies caused by defects in LMNA, including Emery-
Dreifuss muscular dystrophy, atypical Werner syndrome, limb-
girdle muscular dystrophy type 1B, Charcot-Marie-Tooth disease
type 2, dilated cardiomyopathy, Dunnigan-type familial partial
lipodystrophy, mandibuloacral dysplasia with type A lipodys-
trophy, and Hutchinson-Gilford progeria syndrome (HGPS) (2,
3). The relationship between LMNA genotype and phenotype is
highly complex. Several LMNA mutations that cause the same or
similar disorders do not cluster in the same functional region of
the protein (3). Loss or gain of tissue-specific lamin A/C–protein
interactions may explain how LMNA mutations cause such dif-
ferent, though at times overlapping, phenotypes.
Two of the disorders that can be caused by LMNA mutations,
atypical Werner syndrome and HGPS, have some features of
premature aging. A majority of classic Werner syndrome cases
are caused by mutations in WRN, a helicase; however, there are
several mutations in LMNA that have been observed in patients
with atypical Werner syndrome (4). In most cases of HGPS, a de
novo G to T mutation in exon 11 of LMNA activates a cryptic
splice donor. This results in an increase in a form of lamin A,
called progerin, with an internal, in-frame deletion of 50 amino
acids removing a cleavage site important for protein maturation
(5–7). HGPS is a rare premature-aging syndrome that causes an
aged appearance, sclerotic skin, small size, alopecia, bone dys-
plasia, hearing loss, and impaired mobility as a result of joint
contractures (8). Children with HGPS exhibit accelerated ath-
erosclerosis leading to death at a mean age of 14.6 y due to
myocardial infarction or stroke (9).
Cells from patients with HGPS exhibit an irregular nuclear shape
or “blebbing” of the nucleus (5, 10), altered histone modification
patterns, altered transcription (11), impaired DNA damage re-
sponse (12, 13), early senescence, and decreased replicative ability
at later passages (14, 15). These changes at the cellular level are also
seen in cells from persons of advanced age (16). Irregular nuclear
shape and chromatin disorganization have also been reported in
cells from patients with other LMNA mutations (17–21).
Rapamycin and its analogs are of interest as potential new
treatments for disorders associated with deposition of insoluble
protein aggregates (22). Rapamycin inhibits TOR (target of rapa-
mycin), a serine/threonine kinase that responds to environmental
conditions and growth factors by regulating cell growth and me-
tabolism (23). In mammals, the single TOR gene encodes mTOR
(mammalian target of rapamycin), which functions as a component
of two complexes, mTORC1 and mTORC2. Rapamycin inhibits
mTORC1 but can also inhibit mTORC2 with prolonged treatment
(24, 25). When cellular environmental conditions are favorable,
mTORC1 signaling promotes ribosome biogenesis, transcription,
and protein synthesis. If conditions are unfavorable (hypoxia,
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stress, low nutrient levels) or if cells are exposed to rapamycin,
mTORC1 is inhibited and autophagy is promoted (23). Life span
extension has been observed with rapamycin treatment in
Drosophila, yeast, nematodes, and most recently, mouse (26).
HGPS cells treated with rapamycin show a reduction in nu-
clear blebbing, enhanced cell proliferation, and a delay in the
onset of cellular senescence (27). A similar effect was observed
after treatment with the rapamycin analog, everolimus (28). The
proposed mechanism for these improvements with rapamycin is
that treatment promotes the removal of toxic, insoluble aggregates
of progerin by means of the enhanced autophagic-lysosomal path-
way (27). Autophagy normally occurs in the cytoplasm and would
not be expected to remove a nuclear protein like progerin; however,
progerin aggregates become mislocalized during mitosis and can be
found in the cytoplasm (29). Furthermore, there is increasing
evidence that misfolded and aggregated proteins may be disposed of
within the nucleus (30).
Everolimus is generally better tolerated clinically than rapa-
mycin (31), so we chose this mTOR inhibitor for further study. We
hypothesized that treatment with everolimus would improve the
phenotype of cells derived from patients with other laminopathies,
since many of these involve the production of abnormal proteins
that may also form aggregates and contribute to cell death.
Results
Primary fibroblast cell lines with mutations in LMNA were se-
lected for treatment with everolimus (Fig. 1 and Table 1). Such
cell lines are not widely available, but we were able to obtain six:
two lines from patients with atypical HGPS (PSADFN414 and
PSADFN425); two atypical Werner syndrome lines (NORWAY1010
and AG04110); one line from an Emery-Dreifuss muscular dystrophy
Fig. 1. Diagram of the locations of LMNAmutations in the cell lines used in this study. Each putative causative mutation is indicated along with the name of
the cell line that harbors it and the disease it causes. The top left key shows the name of each disorder, and the top right key shows the color code for the
domains of lamin A and/or C. The LMNA gene is not drawn to scale. Adapted with permission from ref. 7.
Table 1. Description of cell lines used including disease, LMNA mutation and clinical phenotype
Cell line Disease Mutation in LMNA Clinical phenotype
AG04110 Atypical Werner
syndrome
Exon 11, heterozygous
c.1733 A>T (p.E578V)
Short stature, dysmorphic features, large coarse brown freckles
over the entire body, thin skin on hands and feet, poor
dentition, scoliosis, atrophic skin changes, beak nose, and high-
pitched voice
NORWAY1010 Atypical Werner
syndrome
Exon 5, heterozygous
c.834 T>G (p.L140R)
Died at age 36 y, cataracts, premature atherosclerosis, gray/thin
hair, scleroderma-like skin, osteoporosis, soft tissue calcification,
hypogonadism, aortic stenosis/insufficiency
GM23780 Emery-Dreifuss
muscular dystrophy
Exon 1, heterozygous
c.104 T>C (p.L35P)
Achieved most motor function milestones and then lost them,
sample collected at age 14 y, clinically affected, diagnostic
muscle biopsy
PSADFN414 Atypical HGPS Exon 11, heterozygous
c.1762T>C (p.C588R)
Small stature, mandibular hypoplasia, dental overcrowding, slow-
growing coarse scalp hair, high narrow palate, thin and
atrophic skin, little s.c. fat, joint pain, osteoarthritis, osteolysis,
mild tricuspid valve regurgitation, sinus arrhythmia
PSADFN425 Atypical HGPS Exon 1, heterozygous
c.331 G>A (p.E111K)
Small stature, mandibular hypoplasia, reduced s.c. fat and muscle
mass, thinned hair, decreased bone density, dental
overcrowding, stiff joints, elevated blood pressure, tricuspid
valve regurgitation, systolic murmur, aortic stenosis at 20.5 y
HGADFN167 Classical HGPS Exon 11, heterozygous
c.1824 C>T (p.G608G)
Classical HGPS phenotype with low body weight, short stature,
muscle contractures, hearing loss, osteoporosis, dysplastic
skeletal changes, dental crowding, narrow tented palate, s.c.
paucity of fat, insulin resistance, scleroderma-like areas, skin
fragility, paucity of scalp hair, and progressive cardiovascular
disease; death at 17.2 y due to cardiac arrest
HGFDFN168 Normal control None (exon 11 sequenced) None (father of HGADFN167, normal control)
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patient (GM23780); and one line from an HGPS patient with the
most common causative mutation (HGADFN167). We also included
the normal cell line HGFDFN168 (father of HGADFN167). For
each experiment, cells were treated with either 0.1 μM everolimus
(dissolved in ethanol) or the same volume of ethanol (vehicle control).
To assess biological effect of the drug treatment, we measured
reduction in the level of phosphorylated ribosomal protein S6
(pRPS6), which is commonly used as a biomarker to reflect
mTOR inhibition. We observed a reduction in pRPS6 levels in
all cell lines after 2 wk of everolimus treatment (Fig. 2).
Lobulations, or blebs, of the nuclear membrane have been ob-
served at a much higher rate in HGPS cells compared to normal
cells, especially after multiple passages in culture. Blebs have also
been observed in cells with other LMNA mutations. We explored
whether everolimus could improve the nuclear morphology of cells
from patients with different laminopathies. Given the limitation of
subjective assessments, we developed a machine vision approach to
identify nuclei in images of immunofluorescence-labeled cells, de-
fine the borders of the nuclei, and measure aspects of the nuclei.
The metric mean negative curvature (MNC) was used to assess the
severity of the blebbing (Fig. 3). Cells were treated three times per
week for 2 wk with everolimus or vehicle control, and then nuclei
were immunofluorescently labeled with a lamin A/C antibody and
imaged. First, we assessed whether nuclear blebbing is a feature of
the six laminopathy cell lines in this study. Two of the vehicle-
treated lines, AG04110 and PSADFN425, did not demonstrate a
difference in blebbing compared with the vehicle-treated normal
control (P = 0.58 and P = 0.25, respectively, Wilcoxon rank sum
test, two sided), so increased nuclear blebbing does not appear to be
associated with these mutations. In most of the cell lines, the me-
dian MNC of the everolimus-treated cells was less than the median
MNC of the control-treated cells, including the normal control (Fig.
4). The one exception was GM23780, which shows a higher median
MNC with everolimus treatment. GM23780 nuclei have an un-
usually elongated shape, which may make MNC a less informative
metric for measuring improvement in this line.
The proliferative ability of HGPS cells in culture is reduced
compared with normal cells, and it has been previously shown that
rapamycin treatment can improve this defect. We observed the
proliferation rates of the laminopathy fibroblasts with everolimus
or control treatment and found that with everolimus treatment,
several of the lines were able proliferate better than their control-
treated counterparts (Fig. 5). The everolimus-treated cells did
show a decrease in proliferation initially, which has been noted
elsewhere (27, 28), but later surpassed the control-treated cells in
most of the lines. Several of the everolimus-treated cell lines
(AG04110, PSADFN414, and PSADFN425) continued growing for
30 d or more past the time when control-treated cells of the same
line stopped dividing. Normal fibroblasts (cell line HGFDFN168)
showed increased proliferation with everolimus treatment as well,
which has been observed previously with rapamycin treatment (27).
Another defect observed in HGPS cells is premature senescence.
To assess senescence, everolimus- and control-treated cells from
each line were stained for β-galactosidase activity. In all of the lines,
we observed β-galactosidase–positive cells in the control-treated
cells, but none in the everolimus-treated cells (Fig. 6 and Fig. S1).
Lastly, we assessed whether everolimus treatment results in a
quantitative reduction in lamin proteins. We did not observe an
overall reduction in lamin A or C in the fibroblast lines after
everolimus treatment for 2 wk (Fig. S2).
Discussion
Fibroblast cells from laminopathy patients with six different LMNA
mutations showed improvement in at least two key phenotypic
measures of cellular health upon everolimus treatment. First, all
everolimus-treated laminopathy cultures showed an increase in
proliferative ability, with three of five lines continuing to proliferate
after control cultures had ceased to grow (AG04110, PSADFN414,
and PSADFN425). Second, all treated cell lines displayed a re-
duction in senescence by β-galactosidase staining. In addition, of
the four laminopathy cell lines that exhibited nuclear blebbing,
three demonstrated significant improvement in nuclear morphol-
ogy (a reduction in nuclear MNC) after everolimus treatment.
A previous study showed that the benefit of rapamycin treat-
ment of HGPS fibroblasts is based, at least in part, on increased
autophagy of the mutant progerin protein (27). Although most of
the laminopathy fibroblast lines studied here do not produce
progerin, they each produce some form of abnormal lamin A
proteins that might well accumulate as insoluble complexes in the
nucleus and cytoplasm after multiple mitoses. We therefore hy-
pothesized that mTOR inhibition could provide benefit for these
cell lines through a similar mechanism, by increasing autophagy
and eliminating aggregated abnormal lamin protein. Unfortunately,
our experiments with autophagy inhibitors in concert with ever-
olimus were unsuccessful due to the extreme cell toxicity of the
autophagy inhibitors. The autophagy inhibitors were not tolerated
for the length of time needed for everolimus treatment.
mTOR inhibitors have shown benefit in mouse models with a
Lmna deletion or mutation. Rapamycin treatment increases survival
in Lmna-knockout homozygous mice, a model that develops dilated
cardiomyopathy and skeletal muscle dystrophy (32). Ramos et al.
demonstrated that mTORC1 signaling is increased in tissues linked
to the pathology and that rapamycin treatment reduces this signaling
and, thus, increases autophagy (32). Unlike the laminopathy cell
lines studied here that have an aberrant form of lamin A and/or C,
these mice have a lack of lamin A and C altogether. Clearly, rapa-
mycin is not improving the phenotype of these mice through clearing
lamin A and/or C, but perhaps clearance of other deleterious pro-
teins is causing the improvement. In LmnaH222P/H222P mice, a model
of Emery-Dreifuss muscular dystrophy, treatment with the rapamy-
cin analog tesirolimus has been shown to improve heart function (33,
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Fig. 2. Reduction in pRPS6 levels with everolimus treatment. Western blots
of RPS6 and pRPS6 are shown for everolimus-treated and vehicle control-
treated cell lines. All cell lines were treated three times per week for 2 wk
with 0.1 μM everolimus (EV) or vehicle control (ctrl). Passage (P) number at
collection is indicated.
MNC= 0.0194 MNC= 0.0537
Fig. 3. MNC is an objective measurement of nuclear blebbing that can be
determined by machine vision. Shown are two example nuclei stained with a
lamin A/C antibody, one unblebbed and one blebbed. The perimeter of each
nucleus, which is used to determine MNC, is shown in red.
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34). Again, an increase in mTORC1 signal was present in disease-
relevant tissue, and treatment increased autophagy, although lamin
A/C aggregates or a reduction in lamin A/C were not observed. It is
possible that improvement in overall autophagy is responsible for
the amelioration of the phenotype observed in both of these
models and in the laminopathy cell lines treated in this study with
everolimus as well.
Previous treatment strategies for HGPS have focused on
farnesyltransferase inhibitors, since the toxic protein in this dis-
order is permanently farnesylated as a result of loss of a cleavage site
used in the final posttranslational step (7). Inhibiting farnesylation
(and thus quantitatively reducing the amount of progerin) has shown
benefit in HGPS cell models (35), mouse models (36), and patients in
a clinical trial (37). The molecular defect in some of the other lam-
inopathies is not the overproduction of a permanently farnesylated
prelamin, but rather the production of a mature lamin containing a
missense mutation in the protein. Although farnesyltransferase in-
hibitors have proved useful in treating HGPS, their use in other
laminopathies does not have the same rationale. Alternative thera-
peutic approaches are needed.
Everolimus is approved for the management of transplant
rejection and for cancer treatment and has been administered to
AG04110
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children over long periods of time with a good safety record. It is
being tested for treatment of HGPS in an ongoing clinical trial
(https://clinicaltrials.gov/). Cellular data presented here, including
improvements in the growth, senescence, and nuclear morphology
of cell lines from several different laminopathies, indicate that
everolimus might also be a viable treatment option for other dis-
orders in this category of rare diseases.
Materials and Methods
Laminopathy Fibroblast Cell Lines and Patient Phenotypes. Cells and information
(genotypeandpatient phenotype) for theHGFDFN168,HGADFN167, PSADFN414,
and PSADFN425 cell lines were obtained from the Cell and Tissue Bank and the
Medical andResearchDatabase, respectively, of the Progeria Research Foundation
(www.progeriaresearch.org). PSADFN414 and PSADFN425 have been described
previously (identified as APS 400.5 and APS 500.3, respectively) (38).
PSADFN425 is a compoundheterozygote for themutation listed in Table 1 and
for LMNA intron 6, 1158-44 C>T. Themutation found in intron 6 is present in the
1000 Genomes Project database (39) and in one of the patient’s unaffected
parents and is unlikely to be causative. AG04110 and GM23780 were purchased
from the Coriell Institute for Medical Research (Coriell Cell Repositories, https://
ccr.coriell.org/) and genotype and patient phenotype information was obtained
from the online listing for those lines. NORWAY1010 was a gift from Junko
Oshima, University of Washington, Seattle, and genotype and patient pheno-
type information was previously published (18).
Control and Experimental Treatments. Cells were treated with media con-
taining 0.1 μM everolimus (S1120; Selleck Chemicals) in ethanol or with media
containing vehicle control (the same volume of ethanol) three times per week
(Monday, Wednesday, and Friday). The media used was Minimum Essential
Media (10370021; Life Technologies) supplemented with 13% heat-inactivated
FBS (10438018; Life Technologies), 1× L-Glutamine (25030081; Life Technolo-
gies), and 1× Antibiotic-Antimycotic (15240096; Life Technologies).
Proliferation Studies. Each cell line was trypsinized and counted, and two 25-cm2
culture-treated vented flasks were seeded with 1 × 105 cells each. The media on
the cells was changed as described above, and split 1:3 when approaching 90%
confluency. One-third of the cells were seeded into a new 25-cm2 flask. Cells
were counted on a Z2 COULTER COUNTER Cell and Particle Counter (Beckman
Coulter), and the media/cell volume was recorded. The total number of cells was
calculated and then multiplied by 3 for each split the line had undergone be-
tween the start of the assay and the count to adjust for cells that were removed
at each split. If the cells were less than 90% confluent 30 d after the last split, the
cells were counted and not cultured further. The data are available in Table S1.
Senescence-Associated β-Galactosidase Assay. Cells from 0.1 μM everolimus-
treated and control-treated flasks that had been growing for the same
amount of time (not necessarily the same passage due to differences be-
tween the proliferation rates of the drug-treated and vehicle control-
treated cells) were trypsinized and seeded onto a six-well plate. HeLa cells
transfected with a β-galactosidase expression plasmid were used as a posi-
tive control, and nontransfected HeLa cells were used as a negative control.
Cells were stained using a senescence-associated β-galactosidase cell staining
kit according to the manufacturer’s protocol (9860; Cell Signaling Technol-
ogies). Photographs were taken on a light microscope at 20× magnification.
Western Blots. ForRPS6/pRPS6and laminA/Cdetection in laminopathyand control
fibroblasts (Fig. 2 and Fig. S2), cells were treated with 0.1 μMeverolimus or vehicle
control three times per week for 2 wk, and the cells were last treated ∼4 to 5 h
before collection. Cells were suspended in 1× LI-COR protein loading buffer di-
luted in ddH2O (928-40004; LI-COR). Cells were boiled for 3 min and cooled at
room temperature for 5 min. Ten micrograms of protein was used per sample,
and NuPAGE Sample Reducing Agent was added before loading (NP0004;
ThermoFisher Scientific). Protein was loaded into each well of a 10% Bis-Tris
gel and electrophoresed in 1× 3-(N-morpholino) propanesulfonic acid buffer.
Proteinwas transferred from thegel to anitrocellulosemembrane (wet transfer)
using an iBlot gel transfer device (Invitrogen), and themembranewas blockedwith
shaking over night at 4 °C in 1:1 1× PBS:Odyssey Blocking Solution (927-
40000; LI-COR). The membrane was incubated with two primary antibodies
(one for the protein of interest and one for the control protein) and two secondary
antibodies (each with shaking at room temperature for 3 and 1 h, respectively, in
1:1 1× PBS:Odyssey Blocking Solution with 0.1% Tween 20 and antibody).
The following primary antibodies were used: S6 Ribosomal Protein (5G10)
Rabbit mAb (2217; Cell Signaling Technology), Phospho-S6 Ribosomal Protein
(Ser235/236) (D57.2.2E) XP Rabbit mAb (4858; Cell Signaling Technology), Anti-
beta Actin antibody (mouse, ab8226; Abcam; used for Fig. 2 and Fig. S2), and
Lamin A/C (N-18) Antibody (goat, sc-6215; Santa Cruz Biotechnology, Inc.; used
for Fig. S2). The following secondary antibodies were used as appropriate:
IRDye 680RD Donkey (polyclonal) Anti-Mouse IgG (926-68072; LI-COR), IRDye
680RD Donkey (polyclonal) Anti-Rabbit IgG (926-68073; LI-COR), IRDye 800CW
Donkey Anti-Mouse IgG (926-32212; LI-COR), IRDye 800CW Donkey Anti-
Rabbit IgG (926-32213; LI-COR), and IRDye 800CW Donkey Anti-goat IgG
(925-32214; LI-COR). Membranes were scanned using a LI-COR Odyssey CLx.
Immunofluorescence. After 2 wk of 0.1 μM everolimus or vehicle control
treatment, cells were trypsinized, counted, and seeded onto eight-chamber
treated culture slides (354108; Corning) at 25,000 cells per well. The cells were
allowed to attach overnight. The next day, the cells were fixed with 4% para-
formaldehyde (15710; Electron Microscopy Science) in 1× PBS and permeablized
with 0.5% Triton X-100 in 1× PBS. Slides were blocked overnight with 4% BSA in
1× TBS at 4 °C. Primary antibody to lamin A/C (MAB3211; Millipore) was diluted
1:50 in 4% BSA in 1× TBS and applied for 5 h at room temperature, and then
washed. Secondary antibody, Alexa Fluor 594 Donkey Anti-Mouse IgG (H+L)
(A21203; Invitrogen) was diluted 1:1,000 in 4% BSA in 1× TBS and applied for
overnight at 4 °C, and then washed. VECTASHIELD Antifade Mounting Medium
with DAPI (H1200; Vector Laboratories, Inc.) was mixed with VECTASHIELD
Antifade Mounting Medium (H1000; Vector Laboratories, Inc.) at a 1:4 ratio and
applied to the wells, and the coverslip was affixed.
Nuclear Imaging and Analysis. Images were taken using a DeltaVision Elite (GE
Healthcare Life Sciences) fluorescent microscope with a 63× oil objective.
Images were run through the MIPAV (Medical Image Processing, Analysis,
and Visualization) application with the Nuclei Segmentation plugin. Seg-
mented nuclei were viewed, and any with improper segmentation were
removed. Remaining segmented nuclei were analyzed with the Nuclei Sta-
tistics plugin to determine the MNC. The Nuclei Statistic plugin was used to
measure the features of the nucleus, including MNC. To determine the MNC,
the perimeter of the nucleus is divided into 100 segments, and all segments
with a negative change in slope (concave) are averaged.
The data are available in Table S2. The cell lines used in this work can be
requested from their respective sources. MIPAV and relevant plugins are
available at https://mipav.cit.nih.gov/.
Fig. 6. Senescence-associated β-galactosidase staining of everolimus-treated and control-treated cells. Cells were treated three times per week with 0.1 μM
everolimus or vehicle control. Passage (P) number of each cell line is indicated in the lower left corner. (Scale bar: 100 μm). All control lines have β-galactosidase–
positive cells (indicated by blue staining), but everolimus-treated lines are negative.
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